Background {#Sec1}
==========

Leprosy is a neglected disease caused by *Mycobacterium leprae* that affects the skin and peripheral nerves. Although treatment exists, access is limited and if it is not initiated early in the course of the disease, the control is suboptimal and permanent disabling sequelae can occur \[[@CR1]\]. On the other hand, research on leprosy is scarce, limiting the development of new strategies. Additionally, in the general population leprosy is feared and misunderstood. Patients, who suffer this disease, since biblical times, are victims of ostracism, stigma and neglect in many cases \[[@CR2]\].

Even when the prevalence of this disease has significantly decreased, and most previously highly endemic countries have reached erradication (defined as a registered prevalence rate of \< 1 case/10000 population), it continues to be a global health concern \[[@CR3]\]. In 2014, the World Health Organization (WHO) estimated that 213,899 new patients were diagnosed globally. Most of them come from developing countries such as Brazil, India and Indonesia. These nations accounted for 81% of new cases \[[@CR4]\].

The best treatment regimen available continues to be controversial with limited evidence support. In 1981, the WHO developed, by consensus, a multidrug therapy (MDT) with dapsone and rifampin for 6 to 12 months for paucibacillary (PB) while clofazimine was added and the length of therapy extended to 24 months for multibacillary (MB) leprosy \[[@CR5]\]. These recommendations were reformulated in 1998, reducing the treatment duration to 6 and 12 months respectively, mainly based on economic reasons \[[@CR6]\]. On the other hand, the National Hansen's Diseases Programs (NHDP) in Peru continues to favors a longer duration of therapy \[[@CR7]\]. Recently, other drugs as minocycline, ofloxacin, levofloxacin, clarithromycin and moxifloxacin have shown to be effective against *M. leprae* \[[@CR8]\].

Considering the lack of an accurate quantitative endpoint (noncultivable pathogen), and a very long observation period for identification of relapse (approximately 15 to 20 years), conducting a trial to compare antibiotic regimens in this disease results extremely difficult, leading to a weakness and lack of evidence. Therefore, we conducted a systematic review to evaluate the effectiveness and safety of the WHO antibiotic regimen for the treatment of PB and MB leprosy compared to other available regimens.

Methods {#Sec2}
=======

This review was reported following the Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CR9]\].

Eligibility criteria {#Sec3}
--------------------

Following our predesign protocol we included randomized controlled trials (RCTs), quasi-randomized trials, and comparative observational studies (cohorts and case-control studies) that enrolled patients of any age with PB or MB leprosy who were treated with any of the leprosy antibiotic regimens established by the WHO in 1982 and used any other antimicrobial regimen as a controller.

Information sources and search {#Sec4}
------------------------------

An experienced librarian (LJP) with expertise in conducting systematic reviews designed and conducted the electronic search strategy with input from the study investigators. We searched multiple electronic databases (Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Database of Systematic Reviews, Ovid Cochrane Central Register of Controlled Trials, Scopus, and LILACS) from 1982 to July 2018 without any language restriction. Controlled vocabulary supplemented with keywords was used to search for the topics of leprosy and WHO multidrug therapy (MDT), as well as to limit the search to randomized trials and observational studies conducted in humans. The detailed search strategy is listed in Additional file [1](#MOESM1){ref-type="media"}. This search was complemented by a manual search that included, reviewing the reference lists of the eligible primary studies, narrative reviews and queried experts.

Study selection {#Sec5}
---------------

Two independent reviewers screened all abstracts and titles and selected potentially eligible studies for full-text assessment. Disagreements were included during this phase. Upon retrieval of the full text version of potentially eligible studies, the review process was repeated using pre-defined eligibility criteria. Disagreements were resolved by consensus (reviewers discussed the study and reached a consensus); when this was not possible, by arbitration (a third reviewer). We achieved almost perfect agreement (k = 0.9) during this phase.

Data collection {#Sec6}
---------------

Data were extracted using a pre-designed, piloted extraction form. Working in duplicates and independently reviewers extracted the following variables from each study: study characteristics, baseline patient characteristics, intervention details, and outcomes of interest. Disagreements were resolved by consensus.

Primary efficacy outcomes included: 1) Complete clinical cure, defined as full regression of the lesions; 2) Clinical improvement of the lesions, defined by a clinical criteria; 3) Relapse rate, defined as the presence of the disease after completing the treatment (clinical or bacteriological or therapeutic criteria) \[[@CR10]\]; 4) Treatment failure, defined as persistence or worsening of skin lesions and failure to improve the bacillary index for MB leprosy. Bacillary index (BI) improvement and neuritis were considered secondary efficacy outcomes. Neuritis was considered if participants reported pain during the interview or when participants complains of pain in one or more peripheral nerve trunks of the limb(s) during the period of the treatment.

Regarding safety outcome, we evaluated severe side effects (defined as a side effect that forced the patient to stop the treatment), and mild to moderate side effects. Also, we evaluated immunological reactions: type I (reverse reaction), and type II (erythema nodosum leprosorum - ENL).

Author contact {#Sec7}
--------------

We contacted corresponding authors of each study twice within 2 weeks via e-mail or by phone or mail when e-mail was not available if additional information was required.

Quality assessment {#Sec8}
------------------

We used the Cochrane Collaboration's tool for assessing risk of bias \[[@CR11]\] to evaluate the methodological quality of the included RCTs. This was assessed independently by duplicate for each study. For observational studies, we used the Newcastle-Ottawa Scale \[[@CR12]\].

Statistical analysis and data synthesis {#Sec9}
---------------------------------------

We summarized the qualitative data (eg. study population, design, intervention, comparison, outcomes) of the included studies in tables. If meta-analysis was appropriate, data was pooled using a random effects model to estimate the treatment effects reported as relative risk (RR) with 95% confidence intervals (CI) \[[@CR13]\] for dichotomous outcomes and mean difference (MD) or standardized mean difference (SDM) with 95% CI for continuous outcomes. Statistical heterogeneity was assessed using I^2^ statistic \[[@CR14]\]; I^2^ values over 50% indicated significant heterogeneity across studies' populations and interventions. In case data were insufficient for meta-analysis, a descriptive summary of the outcome findings was reported per categorization of type of leprosy (PB and MB). If the primary studies did not report standard deviations so they had to be inputted using the other studies as reference \[[@CR15]\].

Assessment of publication bias {#Sec10}
------------------------------

The assessment of publication bias was unfeasible due to the small number of trials \[[@CR15]\].

Results {#Sec500}
=======

Search results and study description {#Sec11}
------------------------------------

The primary search strategy identified 480 references. After initial screening, 135 studies were eligible to full text screening. Finally, 25 studies (22 RCTs, a case-control study and 2 non-randomized trial) met our inclusion criteria and were included in our review (Fig. [1](#Fig1){ref-type="fig"}). One study does not have the full text available and we contacted the corresponding author without getting an answer. Also, another author was contacted to ask the author about the study design without a successful answer. No unpublished studies were identified. Fig. 1Flowchart of the study

The included studies (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}) enrolled 8214 patients with a mean age of 35.2 years (range: 6 to 75 years). Eleven studies evaluated patients with PB leprosy (4281 patients), while 9 evaluated patients with MB leprosy (3869) patients) and 1 included patients from both groups. Follow up period ranged from 3 months to 12 years. All the studies were conducted in the developing world, being India the most common country (11 studies). Table 1Study characteristics in Paucibacillary LeprosyStudyStudy DesignCountryFollow Up (years)NAge (Years)DiagnosisControl UsedEvaluated Outcome2--3 LMT, 2001 \[[@CR16]\]RCTIndia1.5236Children and adultsClinical and bacteriological^a^ROM (single monthly dose, children were given half the dose)-Clinical score-Lesion resolution-Tx failureBabu, 1997 \[[@CR17]\]RCTMulticenter1.51483Mean 23.5Clinical and bacteriological^a^ROM (single monthly dose)Clinical scoreBalagon, 2010 \[[@CR18]\]RCTPhillipines12124MDT:33.5±13.2 35.1±15.2NR28 days of RFP + ofloxacin for 4w then 5 m of placebo-Relapse-CureBathe,1986 \[[@CR19]\]RCTIndia18019--45Clinical, bacteriological, immunological, histologicalMDT + clofazimine in alternative days for 6 mClinical scoreDeshmuk, 2003 \[[@CR20]\]RCTIndia0.53223 ≦ 30 years and 9 \> 30 yearsClinical and bacteriological^a^ROM (single monthly dose)Clinical and histopathological scoreEmmanuel, 2005 \[[@CR21]\]RCTIndia251Children and adultsClinical and histologicalROM (single monthly dose)Clinical scoreKatoch, 1999 \[[@CR22]\]RCTIndia2300NRNRMDT + clofazimine-Active disease/signs of activity-Mitsuda reaction-RelapseKumar 2015 \[[@CR23]\]RCTIndia8268Mean 38.3Skin lesions and nerve involvementROM (Single monthly dose)Cure and relapseManickam 2012 \[[@CR24]\]RCTIndia31526Mean 27Skin lesions and nerve involvementROM (single dose, children were given half the dose)-Clinical score-Complete clearanceMathai, 1991 \[[@CR25]\]RCTIndia2547--67NRMDT + dapsoneMitsuda reactionOrege, 1990 \[[@CR26]\]RCTKenya0.6127NRClinicalMDT + RFP + dapsoneClinical scoreRao, 2009 \[[@CR27]\]Not randomizedIndia232NRClinicalRFP + dapsone + clofazimine ×  6 mClinical and histopathological score*Abbreviations*.- *BI* Bacilar index, *MDT* Multidrug Treatment (WHO), *NR* Not reported, *PB* Paucibacilar, *RFP* Rifampin, *ROM* Rifampin-ofloxacin-minocycline, *Tx* Treatment, *RCT* Randomized Controlled Trial^a^No further details provided Table 2Study characteristics in Multibacillary LeprosyStudyStudy DesignCountryFollow Up (years)NAge (Years)DiagnosisControl UsedEvaluated OutcomeBalagon 2011 \[[@CR28]\]CohortPhilippines25896--73NRMDT 2yType II reactionBathki, 1992 \[[@CR29]\]RCTIndia216NRClinical and smearMDT + vaccineBIFajardo, 2009 \[[@CR30]\]RCTPhilippines12148315--64Clinical and smear-MDT 1y- 1 month of daily RFP + ofloxacin-MDT 1y + 1-month daily RFP/ofloxacin-Relapse-Skin smearFernandes Pena 2012 \[[@CR31]\]RCTBrazil4.9613Mean 40.15NRMonthly RFP, dapsone and clofazimine daily × 6 mType I or II or pure neuritisGunawan, 2018 \[[@CR32]\]RCTIndonesia0.251441. 71±12.53BI and smearclarithromycin+ dapsone+ clofazimineBIJadhav, 1992 \[[@CR33]\]RCTIndia288Mean 24SmearRFP daily for 9 months and then 1 month till the end of 2 years + dapsone + clofazimine daily-BI-Morphological indexMaghanoy, 2018 \[[@CR34]\]RCTPhilippines2100Median 30NRMDT + 12 months of clofazimineType II reactionOliveira Penna. 2017 \[[@CR35]\]RCTBrazil5613Mean 40.2NRRFP + dapsone + clofazimine × 6 m-BI-Type I and II reactions-Disability-Relapse rateRao 2009 \[[@CR27]\]Not randomizedIndia232NRClinicalRFP + dapsone + clofazimine × 6 mClinical and histopathological scoreSampoonachot, 1997 \[[@CR36]\]RCTThailand66012--75NR-MDT + ofloxacin.- ofloxacin + clofazimine, then MDT-BI-Histological improvementShaw, 2003 \[[@CR37]\]Not randomizedIndia24437.2 ± 14.3NRRFP + clofazimine+ acedapsone + dapsoneBISouza Cunha 2012 \[[@CR38]\]RCTBrazil7 after the end of tx198NRUntreated MB with BI ≧ 2-MDT 1y + 1 m of ofloxacin-MDT 1y + 1 m of daily ofloxacin-MDT 1y + daily RFPRelapseTejasvi, 2006 \[[@CR39]\]RCTIndia13027.67 ± 13.08 31.50 ± 17.03NRRFP+ sparfloxacin + clarithromycin + minocycline-BI-Morphological index-Histopathology-Clinical evaluationVillahermosa, 2004 \[[@CR40]\]RCTPhilippines2. Additional 8y2116--59Clinical and smear (\>  1 of 6 smear sites having a BI ≧ 1)ROM (24 consecutive monthly observed doses of rifampin (600 mg), ofloxacin (400 mg), and minocycline (100 mg).Lesion resolution*Abbreviations*.- *BI* Bacilar index, *MB* Multibacilar; *MDT* Multidrug Treatment, *NR* Not reported, *RFP* Rifampin, *ROM* Rifampin-ofloxacin-minocycline *Tx* Treatment; *RCT* Randomized Controlled Trial

Comparison treatments varied between studies. The most common treatment was a single monthly dose of rifampin, ofloxacin and minocycline (ROM) used in 8 studies (6 of PB and 2 of MB leprosy). The outcomes evaluated were also markedly heterogeneous, as it can be seen in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.

Quality assessment {#Sec12}
------------------

The overall risk of bias of the included trials was considered moderate to high. The vast majority of the studies did not clearly report the items evaluated. Most of the included trials reported they attrition rate during the follow up (18 out of 20), with a mean of 10.5% (Fig. [2](#Fig2){ref-type="fig"}). One observational study was included. Quality was evaluated using the Newcastle- Ottawa scale. Details are presented in Additional file [2](#MOESM2){ref-type="media"}. Fig. 2Risk of bias of the selected studies

Outcomes of interest {#Sec13}
--------------------

### Efficacy outcomes {#Sec14}

#### Complete clinical cure {#FPar1}

Complete clinical cure was evaluated in 9 studies that included patients with PB leprosy. It was not evaluated in MB leprosy.

A meta-analysis of 5 studies comparing MDT vs. ROM did not show statistically significant difference between them after 6 months of treatment (RR 1.06, 95% CI 0.88--1.27, *p* = 0.56). When the same comparison was evaluated at the end of the study period (range 6--36 months) in 6 studies, ROM was not better than MDT (RR 1.01, 95% CI 0.78--1.31, *p* = 0.93). The studies with more participants that were included in the analysis had significant and contrary results with RR of 1.14 (95%CI 1.02--1.27) by Babu et al., 1997 and 0.73 (95% CI 0.69--0.77) by Manickam et al., 2012 (Fig. [3](#Fig3){ref-type="fig"}a and b). Fig. 3Complete cure in patients with PB leprosy: MDT vs. ROM. **a**. At 6 months **b**. At the end of follow-up period

The addition of clofazimine to PB MDT did not show significant improvement. This and other available comparisons are shown in Table [3](#Tab3){ref-type="table"}. Table 3Efficacy OutcomesComplete Clinical CureStudyPatientsComparisonFollow upRR95% CI*p* valueBalagon, 2010 \[[@CR18]\]PBMDT vs. 28 days of RFP + ofloxocin for 4w then 5 months of placebo6 m4.22.25--7.85\< 0.0512 m0.930.80--1.090.38Bathe, 1986 \[[@CR19]\]MDT vs. MDT+ clofazimine in alternative days for 6 m6 m1.250.77--2.040.3724 m1.090.93--1.270.29Orege, 1990 \[[@CR26]\]MDT vs. Modified MDT (MDT + RFP + dapsone)^a^6 m0.760.61--0.950.02Clinical ImprovementStudyPatientsComparisonFollow upMDTControlRao, 2009 \[[@CR27]\]PBMDT vs RFP + dapsone + clofazimine (good)24 m6/11 (52%)7/9 (78%)MDT vs RFP + dapsone + clofazimine (moderate)3/11 (27%)2/9 (22%)MBMDT vs RFP + dapsone + clofazimine (good)13/17 (77%)1/4 (25%)MDT vs RFP + dapsone + clofazimine (moderate)3/17 (17%)NoneSampoonachut, 1997 \[[@CR36]\]MDT vs. MDT + ofloxacin.36 m66.70%73.30%MDT vs. ofloxacin + clofazimine, then MDT66.70%76.50%Tejasvi, 2006 \[[@CR39]\]MDT vs. RFP + Sparfloxacin + clarithromycin + minocycline12 m66.66%73.92%Villahermosa, 2004 \[[@CR40]\]^b^MDT vs. ROM96 m22 points20 pointsRelapseStudyPatientsComparisonFollow upRR95% CI*p* valueBalagon, 2010 \[[@CR18]\]PBMDT vs. 28 days of RFP + ofloxacin for 4w then 5 m of placebo12 m1.760.16--18.880.64Katoch, 1999 \[[@CR22]\]MDT vs. MDT+ clofazimine24 m50.24--103.280.3Kumar, 2015 \[[@CR23]\]MDT vs. ROM24 m0.50.05--5.450.5796 m1.70.94--3.070.08Manickam, 2012 \[[@CR24]\]MDT vs. ROM6 m1.430.56--3.640.46Fajardo 2009 \[[@CR30]\]MBMDT 2y vs. MDT 1y + 1 month daily RFP/ofloxacin144 m0.510.05--5.460.58MDT 2y vs. 1 month daily RFP/ofloxacin0.110.02--0.870.04MDT 2y vs. MDT 1 y0.050.01--0.37\< 0.05Olivera Penna, 2017 \[[@CR35]\]MDT vs. RFP+ dapsone + clofazimine × 6 m60 m0.160.02--1.290.08Souza Cunha, 2012 \[[@CR38]\]MDT 1y vs. MDT x 2y84 m2.590.13--52.170.53MDT 1y vs. MDT + ofloxacin1.040.15--7.100.97MDT 1y vs. ofloxacin + RFP0.130.03--0.51\< 0.05Villahermosa, 2004 \[[@CR40]\]MDT vs. ROM96 mNo events reportedBIStudyPatientsComparisonFollow upMD95% CI*p* valueBathki, 1992 \[[@CR29]\]MBMDT vs. MDT + vaccine24 m1.30.48, 2.12\< 0.05Gunawan 2018 \[[@CR32]\]MDT vs. CDC3 m0.03−0.03,0.090.75Jadav, 1992 \[[@CR33]\]MDT vs. RFP + dapsone + clofazimine24 m0.410.12, 0.70\< 0.05Olivera Penna, 2017 \[[@CR35]\]MDT vs. RFP+ dapsone + clofazimine × 6 m60 m− 0.15−1.06,0.760.34Sampoonachut, 1997^c^ \[[@CR36]\]MDT vs. MDT + ofloxacin.36 m−0.07− 0.48, 0.340.74MDT vs. Ofloxacin + clofazimine, then MDT−0.68−1.10, − 0.26\< 0.05Shaw, 2003^c^ \[[@CR37]\]MDT vs. RFP + clofazimine+ acedapsone + dapsone24 m0.1− 0.34, 0.540.66*Abbreviations*. - *BI* Bacillary index, *CDC* Clarithromycin+ dapsone+ clofazimine, *m* Months, *MDT* Multidrug treatment, *ROM* Rifampin, ofloxacin and minocycline^a^Included a period of direct observation^b^Maximum Improvement score at the end of treatment; no other information reported^c^SD not reported

#### Clinical improvement {#FPar2}

This outcome was assessed in 5 studies evaluating PB leprosy and in 3 evaluating MB leprosy. All of them used clinical scores that considered the characteristics of the lesions. Evaluated criteria included erythema, hypopigmentation, infiltration, anesthesia, nerve involvement and size. Since the scoring systems were not consistent between studies, we decided to analyze this outcome using standardized mean difference (SMD).

A meta-analysis of 4 studies comparing MDT vs. ROM in patients with PB leprosy showed a difference between both treatments (Standard mean difference − 1.33 (95% CI -1.43- -1.23)). However, this difference was led by one study with significant results and high number of participants (Manickam 2012), additionally the I^2^ show great heterogeneity (Fig. [4](#Fig4){ref-type="fig"}). Also, the addition of clofazimine to MDT did not show any significant improvement in this population (SMD 0.28, 95% CI -0.16-0.72, *p* = 0.22). Fig. 4Clinical improvement in patients with PB leprosy: MDT vs. ROM at the end of follow up period

Two of the studies (Sampoonachut 1997 and Tejasvi 2006) evaluating patients with MB leprosy reported clinical improvement as a dichotomous outcome; none of them reported enough information for the development of a pooled estimated. Villahermosa 2004 reported an improvement score (Table [3](#Tab3){ref-type="table"}).

#### Treatment failure {#FPar3}

Three studies evaluating PB leprosy patients included treatment failure as their outcomes. These studies evaluated MDT vs. ROM in PB leprosy and no statistically significant difference between the treatment arms was found (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Treatment failure in patients with PB leprosy: MDT vs. ROM at the end of follow up period

#### Relapse {#FPar4}

This outcome was evaluated in 8 studies. Two studies used ROM as their comparison for patients with PB leprosy and one for MB leprosy. The pooled estimate of the studies in patients with PB leprosy showed no difference between both regimes (RR 1.62, 95% CI 0.98--2.67, *p* = 0.06) but there seem to be a tendency to favor ROM (Fig. [6](#Fig6){ref-type="fig"}). The big difference in follow up periods complicates the interpretation of this estimate (6 months vs. 8 years). Additionally, the study evaluating MB leprosy did not report any relapses. Fig. 6Relapse rate in patients with PB leprosy: MDT vs. ROM at the end of follow up period

None of the regimes evaluated showed any benefit over MDT for patients with PB leprosy or MB leprosy (Table [3](#Tab3){ref-type="table"}).

#### Bacillary index (BI) improvement {#FPar5}

BI was exclusively reported for MB leprosy. Six studies evaluated this outcome. In this case, most of the alternate regimes achieved better reductions of BI compared to MDT. Detailed results are reported in Table [3](#Tab3){ref-type="table"}.

### Safety outcomes {#Sec15}

#### Side effects {#FPar6}

We intended to evaluate mild-moderate and severe side effects independently; unfortunately, most studies did not report their outcomes in this way. The development of side effects was analyzed as a single outcome.

Three studies reported side effects in patients with PB leprosy. No statistically significant difference was seen in patients receiving MDT or ROM (Fig. [7](#Fig7){ref-type="fig"}). Fig. 7Adverse events in patients with PB leprosy: MDT vs. ROM at the end of the follow up period

This outcome was reported in 4 studies evaluating patient with MB leprosy. Each study evaluated a different comparison. Individual estimates are reported in Table [4](#Tab4){ref-type="table"}. Table 4Safety Outcomes and Immunological ReactionsSide EffectsStudyPatientsComparisonFollow upRR95% CI*p* valueBalagon, 2010 \[[@CR18]\]PBMDT vs. 28 days of RFP + ofloxacin for 4w then 5 m of placebo12 m0.380.10--1.390.14Gunawan 2018 \[[@CR32]\]MBMDT vs. CDC3 mUnable to analyzeTejasvi, 2006 \[[@CR39]\]MDT vs. RFP + sparfloxacin + clarithromycin + minocycline12 m0.10.01--1.560.1Shaw, 2003 \[[@CR37]\]MDT vs. RFP + clofazimine+ acedapsone + dapsone24 m1.420.58--3.470.44Type I reactionStudyPatientsComparisonFollow upRR95%CIp valueOrege, 1990 \[[@CR26]\]PBMDT vs. MDT + RFP + dapsone^a^6 m1.150.58--2.270.69Fernandes Pena 2012 \[[@CR31]\]MBMDT vs. Monthly RFP, dapsone and clofazimine daily × 6 m60 m1.10.86--1.410.44Sampoonachut, 1997 \[[@CR36]\]MDT vs. MDT + ofloxacin12 m2.110.21--21.360.53MDT vs. Ofloxacin + clofazimine, then MDT10.16--6.381Shaw, 2003 \[[@CR37]\]MDT vs. RFP + Clofazimine+ Acedapsone + dapsone24 m1.780.53--5.970.35Tejasvi, 2006 \[[@CR39]\]MDT vs. RFP + sparfloxacin + clarithromycin + minocycline12 m0.210.01--3.710.29Villahermosa, 2004 \[[@CR40]\]MDT vs. ROM96 m0.910.37--2.230.83Type II reactionStudyPatientsComparisonFollow upRR95% CI*p* valueBabu, 1997 \[[@CR17]\]PBMDT vs. ROM18 mNo events reportedBalagon, 2011 \[[@CR18]\]MBMDT 1y vs. MDT 2y24 m1.531.05--2.230.03Fernandes Pena 2012 \[[@CR31]\]MDT vs. Monthly RFP, dapsone and clofazimine daily × 6 m60 m1.150.72--1.840.56Jadhav, 1992 \[[@CR33]\]MDT vs. RFP + dapsone + clofazimine24 m0.220.07--0.720.01Maghanoy, 2018 \[[@CR34]\]MDT vs. MDT + 12 months of clofazimine24 m0.860.52--1.400.54Sampoonachut, 1997 \[[@CR36]\]MDT vs. MDT + ofloxacin.24 m0.70.13--3.750.68MDT vs. ofloxacin + clofazimine, then MDT10.16--6.381Shaw, 2003 \[[@CR37]\]MDT vs. RFP + clofazimine+ acedapsone + dapsone24 m0.440.04--4.450.49Tejasvi, 2006 \[[@CR39]\]MDT vs. RFP + sparfloxacin + clarithromycin + minocycline12 mNo events reportedVillahermosa, 2004 \[[@CR40]\]MDT vs. ROM96 m0.910.16--5.300.92NeuritisStudyPatientsComparisonFollow upRR95% CI*p* valueManickam, 2012 \[[@CR24]\]PBMDT vs. ROM6 m0.5\[0.05, 5.49\]0.57Bathe, 1986 \[[@CR19]\]MDT vs. MDT+ clofazimine24 m4\[0.47, 34.24\]0.21Katoch, 1999 \[[@CR22]\]MDT vs. MDT+ clofazimine24 mNo events reportedFernandes Pena 2012 \[[@CR31]\]MBMDT vs. RFP, dapsone and clofazimine × 6 m60 m0.640.45, 0.920.01Jadhav, 1992 \[[@CR33]\]MDT vs. RFP + dapsone + clofazimine24 m0.290.03--2.690.28Sampoonachut, 1997 \[[@CR36]\]MDT vs. MDT + ofloxacin24 m2.110.21, 21.360.53MDT vs. ofloxacin + clofazimine, then MDT10.16--6.381Shaw, 2003 \[[@CR37]\]MDT vs. RFP + clofazimine+ acedapsone + dapsone24 m1.190.31--4.510.8*Abbreviations* - *BI* Bacillary index, *CDC* Clarithromycin+dapsone+clofazimine, *RFP* Rifampin; m: months, *MDT* Multidrug treatment, *ROM*, rifampin, ofloxacin and minocycline^a^Included a period of direct observation,

### Immunological reactions {#Sec16}

#### Type I reaction {#FPar7}

This outcome was evaluated in 11 studies (6 PB and 5 MB). A meta-analysis comparing MDT vs. ROM in patients with PB leprosy did not show a statistically significant difference between the interventions (RR 0.99, 95%CI 0.31--3.18, *p* = 0.99, Fig. [8](#Fig8){ref-type="fig"}). Other studies evaluating this outcome are reported in Table [4](#Tab4){ref-type="table"}. Fig. 8Type I reaction in patients with PB leprosy: MDT vs. ROM at the end of the follow up period

#### Type II reaction {#FPar8}

This outcome was evaluated in 9 studies (1 PB and 8 MB). We were not able to develop a meta-analysis. In patients with MB leprosy the combination of dapsone, rifampin and clofazimine showed a statistically significant reduction in the development of type II reaction. On the other hand, the use of MDT regimen for 2 years increased the development of this outcome in the same population when compared to the use of MDT for 1 year. No other statistically significant differences were observed (Table [4](#Tab4){ref-type="table"}).

#### Neuritis {#FPar9}

The development of neuritis was evaluated in 7 studies (3 PB and 4 MB). When MDT was compared to rifampin, dapsone and clofazimine for 6 months in patients with MB leprosy a statistically significant difference between groups was seen (Table [4](#Tab4){ref-type="table"}).

Discussion {#Sec17}
==========

Main findings {#Sec18}
-------------

This study aimed to summarize all the evidence available on WHO MDT treatment effectiveness, safety and immunological reactions for leprosy. One of the aspects that surprised us the most was to see the poor scientific production for a thousand-year-old disease, the lack of standardization in definition of diagnostic criteria, outcome objectives and time for follow up and if we add to this the poor methodological quality of the majority of studies found, show us a situation that support the denomination and let us understand what leprosy is a neglected disease.

It was precisely this potentially high risk of bias studies that did not let bring a consensus: MDT seems to have a better treatment outcome (clinical improvement) compared with ROM at the end of the follow up period, however we did not find differences in complete cure at 6 months of treatment or at the end of follow up period. When MDT is compared with other treatment, we did not find differences in treatment outcomes.

MDT, as is noted above, had almost no difference in a better response for cured and reduced relapse rate, compared with ROM and other treatments schemes, since most of the magnitudes of these differences are small. However, these schemes had a great success rate after 1 or 2 years of follow-up. These results can confirm the useful role of MDT in leprosy treatment, however also reveals gaps in the evidence to improve it: there is lack of information about adherence in these long-time treatments (MDT, ROM and others), together with the lack of resistance pattern of relapse cases, this successful treatment scheme can be in jeopardized by the increasing rate of relapse cases and the unknown effect of resistance epidemiology of *M. leprae* \[[@CR8], [@CR41], [@CR42]\]. Recently the new guidelines of WHO states that "The same 3-drug regimen of rifampicin, dapsone and clofazimine may be used for all leprosy patients, with a duration of treatment of 6 months for PB leprosy and of 12 months for MB leprosy. (Strength: conditional, quality of evidence: low)". However, they mentioned that "evidence on the potential benefits and harms of a shorter (6-month) 3-drug regimen was limited and inconclusive, with a potential increase in the risk of relapse. Therefore, the Guideline Development Group determined that there was not enough evidence of equivalent outcomes to support a recommendation to shorten the treatment duration for MB leprosy" \[[@CR43]\]". The decision was taken based in only one study \[[@CR27]\] which, although it shows an interesting design, its non-randomized and has a very low quality of evidence \[[@CR44]\]. Also, the study has not been valued in comparison with other studies, and besides these, its findings had not been supported by a RCT \[[@CR35]\].

Is in this context, where supported treatment are required (leprosy programs were reduced their support in the last years) \[[@CR8]\], new treatment schemes are needed, considering WHO MDT had more than 30 years of use. However, new treatment should be based in evidence and not only in logistical aspects.

Limitations and strengths {#Sec19}
-------------------------

This study has limitations: primary studies showed high risk of bias, specifically regarding allocation and blinding. Also, most of the studies did not report treatment adherence (a factor for poor treatment outcomes) or comorbidities such as HIV/AIDS that can affect treatment outcomes. Other confounders such as age, gender, and previous treatment should be also considered in the analysis. These limitations can affect (in any direction and in magnitude) the measures of associations reported in primary studies. Another limitation of primary studies was the heterogeneous report of treatment outcomes, so a proper comparison between treatments was very difficult, e.g. almost a third part of treatment outcome evaluation was with different clinical scores, which applied diverse items and can be affected by evaluator bias. Future studies evaluating clinical effectiveness of leprosy treatment should be use standard treatment outcomes, with laboratory definitions and/or biomarkers of success, with the aim to compare different settings and clinical characteristics.

Finally, none of these studies reported antibiotic resistance pattern of *M. leprae*. There are reports on drug resistance in leprosy patients \[[@CR45]--[@CR49]\] and can be one of the reasons of the relapse rate increase in the last years \[[@CR50]\]. Considering some of the areas with leprosy had also high incidence of resistant tuberculosis (such us India) and MDT share rifampin as an important drug with sensitive tuberculosis, closer follow-up and drug resistance studies should be done in these areas.

However, it is important to mention that studies with people with leprosy are conducted in low resources settings where sophisticated methods of follow-up are not possible, due to lack of money and interest of higher authorities.

Implications for practice and research {#Sec20}
--------------------------------------

As a stigmatizing disease for centuries, leprosy is nowadays affecting vulnerable populations in the tropics (especially in rural and semi-rural areas), where health systems are weak and other diseases (such as dengue, malaria, HIV/AIDS or tuberculosis) have more preponderance in public health funding \[[@CR51], [@CR52]\]. Health determinants affects in several areas (such as poverty, education, water and sanitation, gender and others), reason why treatment alone is not the most effective way to eliminate the disease \[[@CR53]\]. In addition, leprosy control faces many barriers regarding clinical management, starting with the lack of funding for research, its characteristic as a silent disease, and unavailable measures for prevention (i.e. an effective vaccine). A delayed diagnosis and treatment usually lead to disability, which regardless the success of treatment, will lead to the necessity of access to health care and rehabilitation for long time, sometimes lifelong \[[@CR54]\]. In addition, there are not new drugs in the pipeline to reduce treatment duration, and the only drug in research phase is bedaquiline (which is also one of the new drugs for tuberculosis after more than 30 years of tuberculosis treatment), which showed a bactericidal effect against *M. leprae* in animal models \[[@CR55], [@CR56]\]. Now, Bedaquiline is being tested in a Phase 2 trial (not started yet) for MB leprosy in Brazil \[[@CR57]\], however, as in the case of tuberculosis, we need new drugs that can be combined to reduce the burden of *M. leprae*, specially in an context of increasing antibiotic resistance, providing a safe and short leprosy treatment.

Conclusions {#Sec21}
===========

None of the evaluated regimes showed any benefit over MDT for patients with PB or MB for relapses. The addition of clofazimine to PB MDT did not show significant improvement.

It is necessary to standardize criteria for diagnosis, cure, and follow-up in the search for more and better evidence to fill existing gaps in information that evaluates the new available antibiotics.

Further studies evaluating adherence to the treatment, potential development of drug resistance and short treatment regimens based in evidence are needed to reach the goal of leprosy elimination.
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**Additional file 1.** Search strategy. Search strategies for the different databases. **Additional file 2.** Quality assesment using the Newcastle- Ottawa scale. Quality assessment for non-RCT studies using the Newcastle-Ottawa scale.
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